JPH0853331A - Tooth powder composition - Google Patents
Tooth powder compositionInfo
- Publication number
- JPH0853331A JPH0853331A JP21183594A JP21183594A JPH0853331A JP H0853331 A JPH0853331 A JP H0853331A JP 21183594 A JP21183594 A JP 21183594A JP 21183594 A JP21183594 A JP 21183594A JP H0853331 A JPH0853331 A JP H0853331A
- Authority
- JP
- Japan
- Prior art keywords
- dentifrice composition
- hydroxyapatite
- composition according
- fluoride
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は歯磨組成物に関し、特に
う蝕予防に有効で、性状が経時的にも安定な歯磨組成物
に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a dentifrice composition, and more particularly to a dentifrice composition which is effective in preventing dental caries and has stable properties over time.
【０００２】[0002]
【従来の技術および課題】ハイドロキシアパタイトは、
歯表面を傷つけることなく、う蝕の原因となる歯垢を除
去するとともに、歯の再石灰化を促進し歯を強化させる
こと（登録1553266、特開昭56-73014、登録1557631）、
また口腔内の口臭成分を吸着除去すること（特開平4-23
0315）など種々の効能を有していることが報告されてお
り、これを歯磨組成物に配合することは広く知られてい
る。[Prior Art and Problems] Hydroxyapatite is
To remove dental plaque that causes dental caries without damaging the tooth surface and to promote remineralization of the tooth and strengthen the tooth (Registered 1553266, JP-A-56-73014, Registered 1557631),
It is also necessary to adsorb and remove halitosis components in the oral cavity (Japanese Patent Laid-Open No. 4-23
It has been reported to have various effects such as that of [0315), and it is widely known to incorporate this into a dentifrice composition.
【０００３】ハイドロキシアパタイトは、他の化合物と
容易に反応し、例えば組成物中に可溶性フッ化物が同時
に存在すると、フッ素イオンが、歯のエナメル質のハイ
ドロキシアパタイトに作用する前に、組成物中のハイド
ロキシアパタイトと反応してフルオロアパタイトを形成
し、有効に働くフッ素化合物ではなくなってしまうこと
が知られている。このような問題を克服するため、例え
ば、特開平2-31049では、ハイドロキシアパタイト及び
フッ化物の少なくとも１つをマイクロカプセル化、或は
コーティングすることにより、それぞれが直接接触する
ことを避けている。また同様の考え方で、特公平6-8247
では、ハイドロキシアパタイトの表面に存在するヒドロ
キシ基を特定物質で前処理することにより、それぞれが
直接接触することを避け、可溶性フッ化物との反応を抑
制している。また、特開平3-193726では、ハイドロキシ
アパタイトと可溶性フッ化物を配合した口腔用組成物の
ｐＨを７．０〜１１．０にすることで有効フッ化物の損
失を減少させている。Hydroxyapatite readily reacts with other compounds, for example, when soluble fluoride is present in the composition at the same time, fluoride ions may be present in the composition before they act on the hydroxyapatite of the tooth enamel. It is known that it reacts with hydroxyapatite to form fluoroapatite, and it is no longer a fluorine compound that works effectively. In order to overcome such a problem, for example, in JP-A-2-31049, at least one of hydroxyapatite and fluoride is microencapsulated or coated to avoid direct contact with each other. In addition, in the same way,
In the above, the hydroxy group existing on the surface of hydroxyapatite is pretreated with a specific substance to avoid direct contact with each other and suppress the reaction with the soluble fluoride. Further, in Japanese Patent Laid-Open No. 3-193726, loss of effective fluoride is reduced by adjusting the pH of the oral composition containing hydroxyapatite and soluble fluoride to 7.0 to 11.0.
【０００４】[0004]
【発明が解決しようとする課題】ところが、ハイドロキ
シアパタイトと可溶性フッ化物を配合した歯磨は、長期
間特に高温で放置した場合、また急激な温度変化がおこ
った場合、肌荒れが起こり、ひどい場合には固化がおこ
るため著しく使用感が損なわれるという問題があること
を知見した。この固化の問題については従来の技術で
は、何等ふれられておらず、たとえば特開平3-193726で
示される方法では解決できておらず、ハイドロキシアパ
タイトと可溶性フッ化物を配合した歯磨における経時で
の性状と外観の問題についての解決が必要であった。However, a toothpaste containing hydroxyapatite and a soluble fluoride causes rough skin when left at a particularly high temperature for a long period of time, or when a rapid temperature change occurs, and when it is severe, It was found that there is a problem in that the solidification occurs and the usability is significantly impaired. The problem of this solidification has not been touched in the conventional technology at all, and for example, it has not been solved by the method disclosed in JP-A-3-93726, and the properties of toothpaste containing hydroxyapatite and soluble fluoride with the passage of time have not been resolved. And there was a need to resolve a cosmetic issue.
【０００５】[0005]
【課題を解決するための手段】本発明者らは、このよう
な問題を解決すべく鋭意研究をおこなった結果、安定化
剤としてポリエチレングリコールおよびビタミンＥ誘導
体から選ばれる１種以上を含むことにより、ハイドロキ
シアパタイトと可溶性フッ化物が共に安定に配合され、
性状、外観ともに安定な歯磨組成物を得ることができ、
本発明を完成するに至った。Means for Solving the Problems As a result of intensive studies to solve such problems, the present inventors have found that the stabilizer contains at least one selected from polyethylene glycol and vitamin E derivatives. , Hydroxyapatite and soluble fluoride are both stably mixed,
It is possible to obtain a dentifrice composition having stable properties and appearance,
The present invention has been completed.
【０００６】本発明で用いられる安定化剤であるポリエ
チレングリコールとしては、重合度３００〜６００のも
のが適当であり、重合度３００未満のものは、保水能が
充分でなく、重合度６００をこえるものは、固体である
ため他の成分との相容性が悪くなる。また、その配合量
としては、１〜２０％が好ましく、配合量が１％未満で
は性状、外観の安定化のためには不十分であリ、２０％
をこえると使用感が悪くなる。さらに、ポリエチレング
リコールとハイドロキシアパタイトの重量比が１：０．
５〜１：５０である場合、性状、外観の安定化に特に好
ましい。Polyethylene glycol, which is a stabilizer used in the present invention, has a degree of polymerization of 300 to 600 is suitable, and those having a degree of polymerization of less than 300 have an insufficient water retention capacity and the degree of polymerization exceeds 600. Since they are solids, they have poor compatibility with other components. Further, the content is preferably 1 to 20%, and if the content is less than 1%, it is insufficient for stabilizing the properties and appearance, and 20%.
If it exceeds, the usability will deteriorate. Furthermore, the weight ratio of polyethylene glycol and hydroxyapatite is 1: 0.
The ratio of 5 to 1:50 is particularly preferable for stabilizing the properties and appearance.
【０００７】本発明で用いられる安定化剤であるビタミ
ンＥ誘導体としては、ニコチン酸トコフェロール、酢酸
トコフェロールであることが好ましく、特にニコチン酸
トコフェロールが好ましい。またその配合量は、０．０
１〜１％が好ましく、配合量が０．０１％未満では、性
状、外観の安定化のためには不十分である。さらに、ビ
タミンＥ誘導体とハイドロキシアパタイトが重量比で
１：１〜１：１０００である場合、性状、外観の安定化
に特に好ましい。The vitamin E derivative which is a stabilizer used in the present invention is preferably tocopherol nicotinate or tocopherol acetate, and tocopherol nicotinate is particularly preferred. Moreover, the compounding quantity is 0.0
1 to 1% is preferable, and if the blending amount is less than 0.01%, it is insufficient for stabilizing properties and appearance. Furthermore, when the weight ratio of the vitamin E derivative and hydroxyapatite is 1: 1 to 1: 1000, it is particularly preferable for stabilizing the properties and appearance.
【０００８】本発明で用いられる可溶性フッ化物として
は、モノフルオロリン酸ナトリウム、フッ化ナトリウ
ム、フッ化スズが好ましい。The soluble fluoride used in the present invention is preferably sodium monofluorophosphate, sodium fluoride or tin fluoride.
【０００９】本発明で用いられるハイドロキシアパタイ
トとしては種々選択されるが、その中でも特に平均粒子
経が１〜５０μｍ、より好ましくは３〜３０μｍのもの
が好ましい。平均粒子径が１μｍ未満では作業性が悪
く、５０μｍをこえたものでは使用感が損なわれる。ま
た、ハイドロキシアパタイトは通常１〜５０％、より好
ましくは３〜１０％配合することが望ましく、１％未満
であるとハイドロキシアパタイトの効果がみられず、５
０％をこえると良好な性状が得られにくい。さらに、本
発明で用いられるハイドロキシアパタイトの比表面積は
１００ｍ2 ／ｇ以下が好ましく、比表面積が１００ｍ2
／ｇをこえると、ハイドロキシアパタイトの反応性が高
くなり過ぎ、性状、外観の安定化に悪影響を及ぼす。The hydroxyapatite used in the present invention is selected in various manners, and among them, those having an average particle diameter of 1 to 50 μm, more preferably 3 to 30 μm are particularly preferable. If the average particle size is less than 1 μm, the workability is poor, and if it exceeds 50 μm, the usability is impaired. Further, it is desirable to add hydroxyapatite in an amount of usually 1 to 50%, more preferably 3 to 10%, and if it is less than 1%, the effect of hydroxyapatite is not observed, and
If it exceeds 0%, it is difficult to obtain good properties. Furthermore, the specific surface area of the hydroxyapatite used in the present invention is preferably 100 m 2 / g or less and a specific surface area of 100 m 2
If it exceeds / g, the reactivity of hydroxyapatite becomes too high, which adversely affects the stabilization of the properties and appearance.
【００１０】本発明の歯磨組成物は常法に従って練歯
磨、液状歯磨、錠剤のいずれの剤型にもすることがで
き、必要に応じて適宜な成分、例えば通常の口腔用組成
物に使用される研磨剤としては第二リン酸カルシウム、
第一リン酸カルシウム、第三リン酸カルシウム、炭酸カ
ルシウム、ピロリン酸カルシウム、水酸化アルミニウ
ム、アルミナ、無水ケイ酸、シリカゲル、ケイ酸アルミ
ニウム、不溶性メタリン酸ナトリウム、第三リン酸マグ
ネシウム、炭酸マグネシウム、硫酸カルシウム、ポリメ
タクリル酸メチル、ベントナイト、ケイ酸ジルコニウ
ム、合成樹脂等が使用され、湿潤剤としてはソルビッ
ト、プロピレングリコール、濃グリセリン、ポリエチレ
ングリコール等が使用され、増粘剤としてはカルボキシ
メチルセルロースナトリウム、カラギーナン、キサンタ
ンガム、アルギン酸ナトリウム、ヒドロキシエチルセル
ロース等が使用され、界面活性剤としてはラウリル硫酸
ナトリウム、ラウロイルサルコシンナトリウム、ショ糖
脂肪酸エステル、ラウリン酸ジエタノールアミド、ポリ
オキシエチレン硬化ヒマシ油、ポリオキシエチレン・ポ
リオキシプロピレンブロックコポリマー等が使用され、
その他安息香酸ナトリウム、メチルパラベン等の防腐
剤、、ペパーミント、スペアミント等の精油、ｌ−メン
トール、カルボン、アネトール等の香料素材等の香料、
サッカリンナトリウム、ステビオサイド、ネオヘスペリ
ジルジヒドロカルコン、グリチルリチン、ソーマチン、
ペリラルチン、Ｐ−メトキシシンナミックアルデヒド、
キシリトール等の甘味剤、および塩化セチルピリジニウ
ム、塩酸クロルヘキシジン、トリクロサン、デキストラ
ナーゼ、ムタナーゼ、ヒノキチオール、リゾチーム、ア
ラントイン、グリチルリチン酸ジカリウム、イプシロン
アミノカプロン酸、トラネキサム酸、塩化ナトリウム、
アズレン、イソプロピルメチルフェノール等の有効成分
を本発明の効果を損なわない範囲で配合することができ
る。The dentifrice composition of the present invention can be made into any of dosage forms such as toothpaste, liquid dentifrice, and tablets according to a conventional method, and is used in an appropriate component as necessary, for example, a usual oral composition. Dibasic calcium phosphate as an abrasive
Monobasic calcium phosphate, tribasic calcium phosphate, calcium carbonate, calcium pyrophosphate, aluminum hydroxide, alumina, silicic acid anhydride, silica gel, aluminum silicate, insoluble sodium metaphosphate, magnesium triphosphate, magnesium carbonate, calcium sulfate, polymethacrylic acid Methyl, bentonite, zirconium silicate, synthetic resin or the like is used, as a wetting agent, sorbit, propylene glycol, concentrated glycerin, polyethylene glycol or the like is used, and as a thickener, sodium carboxymethyl cellulose, carrageenan, xanthan gum, sodium alginate, Hydroxyethyl cellulose and the like are used, and as the surfactant, sodium lauryl sulfate, sodium lauroyl sarcosine, sucrose fatty acid ester, lauri Acid diethanolamide, polyoxyethylene hardened castor oil, polyoxyethylene-polyoxypropylene block copolymer or the like is used,
Other preservatives such as sodium benzoate and methylparaben, essential oils such as peppermint and spearmint, and fragrances such as l-menthol, carvone and anethole.
Sodium saccharin, stevioside, neohesperidyl dihydrochalcone, glycyrrhizin, thaumatin,
Perillartine, P-methoxycinnamic aldehyde,
Sweeteners such as xylitol, and cetylpyridinium chloride, chlorhexidine hydrochloride, triclosan, dextranase, mutanase, hinokitiol, lysozyme, allantoin, dipotassium glycyrrhizinate, epsilon aminocaproic acid, tranexamic acid, sodium chloride,
Active ingredients such as azulene and isopropylmethylphenol can be added within a range that does not impair the effects of the present invention.
【００１１】[0011]
【実施例】以下、実施例と実験例により本発明をさらに
詳しく説明する。 実施例１〜１５および比較例１ 実験 表１にしめす練歯磨きを定法に従って製造し、各歯磨に
ついて５５℃で３ヶ月放置後、性状と使用感について次
の評価基準で評価した。 （評価基準） ○：良好 △：やや問題あり ×：問題あり （総合評価） ◎：性状、使用感ともに○である ○：性状、使用感いずれかに△がある ×：性状、使用感いずれかが× であるEXAMPLES The present invention will be described in more detail below with reference to examples and experimental examples. Examples 1 to 15 and Comparative Example 1 Experiment A toothpaste toothpaste shown in Table 1 was produced according to a standard method, and after leaving each toothpaste at 55 ° C. for 3 months, the properties and feeling of use were evaluated according to the following evaluation criteria. (Evaluation criteria) ○: Good Δ: Some problem ×: There is a problem (Comprehensive evaluation) ◎: Both property and feeling of use are ○: There is △ in either property or feeling of use ×: Either of property or feeling of use Is x
【表１】 表１に示す結果より明らかなように、特定重合度のポリ
エチレングリコールとビタミンＥ誘導体から選ばれる一
種または二種以上を含むことにより、性状、外観ともに
安定であることがわかる。[Table 1] As is clear from the results shown in Table 1, it is found that the properties and appearance are stable by containing one or more selected from polyethylene glycol having a specific degree of polymerization and vitamin E derivative.
【００１２】 [0012]
【００１３】 [0013]
【００１４】 [0014]
【００１５】[0015]
【発明の効果】本発明によれば、う蝕予防に有効で、性
状が経時的にも安定な歯磨組成物が得られる。EFFECTS OF THE INVENTION According to the present invention, a dentifrice composition which is effective in preventing dental caries and which has stable properties over time can be obtained.
Claims (12)
物を配合した歯磨において、安定化剤としてポリエチレ
ングリコールおよびビタミンＥ誘導体から選ばれる１種
以上を含むことを特徴とする歯磨組成物。1. A dentifrice composition containing hydroxyapatite and a soluble fluoride, wherein the dentifrice contains one or more selected from polyethylene glycol and a vitamin E derivative as a stabilizer.
アパタイトが重量比で１：０．５〜１：５０である請求
項１記載の歯磨組成物。2. The dentifrice composition according to claim 1, wherein the weight ratio of polyethylene glycol and hydroxyapatite is 1: 0.5 to 1:50.
イトが重量比で１：１〜１：１０００である請求項１記
載の歯磨組成物。3. The dentifrice composition according to claim 1, wherein the vitamin E derivative and the hydroxyapatite are in a weight ratio of 1: 1 to 1: 1000.
トリウム、フッ化ナトリウム、フッ化スズの一種または
二種以上である請求項１記載の歯磨組成物。4. The dentifrice composition according to claim 1, wherein the soluble fluoride is one or more of sodium monofluorophosphate, sodium fluoride and tin fluoride.
００〜６００であることを特徴とする請求項１記載の歯
磨組成物。5. Polyethylene glycol has an average degree of polymerization of 3
The dentifrice composition according to claim 1, wherein the dentifrice composition is from 00 to 600.
ロール、酢酸トコフェロールから選ばれる１種以上であ
る請求項１記載の歯磨組成物。6. The dentifrice composition according to claim 1, wherein the vitamin E derivative is one or more selected from tocopherol nicotinate and tocopherol acetate.
ロールである請求項１記載の歯磨組成物。7. The dentifrice composition according to claim 1, wherein the vitamin E derivative is tocopherol nicotinate.
２０％である請求項１記載の歯磨組成物。8. The blending amount of polyethylene glycol is 1 to
20% dentifrice composition according to claim 1.
ェロールの配合量が０．０１〜１％である請求項１記載
の歯磨組成物。9. The dentifrice composition according to claim 1, wherein the blending amount of tocopherol nicotinate and tocopherol acetate is 0.01 to 1%.
が１〜５０μｍである請求項の１記載の歯磨組成物。10. The dentifrice composition according to claim 1, wherein the hydroxyapatite has an average particle size of 1 to 50 μm.
〜５０重量％である請求項１記載の歯磨組成物。11. The compounding amount of hydroxyapatite is 1.
The dentifrice composition according to claim 1, which is about 50% by weight.
１００ｍ2／ｇ以下である請求項１記載の歯磨組成物。12. The dentifrice composition according to claim 1, wherein the specific surface area of hydroxyapatite is 100 m 2 / g or less.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21183594A JP3285452B2 (en) | 1994-08-11 | 1994-08-11 | Toothpaste composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21183594A JP3285452B2 (en) | 1994-08-11 | 1994-08-11 | Toothpaste composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0853331A true JPH0853331A (en) | 1996-02-27 |
| JP3285452B2 JP3285452B2 (en) | 2002-05-27 |
Family
ID=16612382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP21183594A Expired - Fee Related JP3285452B2 (en) | 1994-08-11 | 1994-08-11 | Toothpaste composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3285452B2 (en) |
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110082214A1 (en) * | 2008-05-09 | 2011-04-07 | Gruenthal Gmbh | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
| US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
| US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
| US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
| US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
| US10130591B2 (en) | 2003-08-06 | 2018-11-20 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
| US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
| US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US10493033B2 (en) | 2009-07-22 | 2019-12-03 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
-
1994
- 1994-08-11 JP JP21183594A patent/JP3285452B2/en not_active Expired - Fee Related
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10369109B2 (en) | 2002-06-17 | 2019-08-06 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
| US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10130591B2 (en) | 2003-08-06 | 2018-11-20 | Grünenthal GmbH | Abuse-proofed dosage form |
| US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US10675278B2 (en) | 2005-02-04 | 2020-06-09 | Grünenthal GmbH | Crush resistant delayed-release dosage forms |
| US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
| US9161917B2 (en) * | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
| US20110082214A1 (en) * | 2008-05-09 | 2011-04-07 | Gruenthal Gmbh | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
| US10493033B2 (en) | 2009-07-22 | 2019-12-03 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
| US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
| US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
| US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
| US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US10864164B2 (en) | 2011-07-29 | 2020-12-15 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
| US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3285452B2 (en) | 2002-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3285452B2 (en) | Toothpaste composition | |
| JP3345133B2 (en) | Toothpaste composition | |
| US3227617A (en) | Fluoride dentifrice composition | |
| JPS6234013B2 (en) | ||
| CA1196286A (en) | Peroxydiphosphate toothpaste composition | |
| JPH1121219A (en) | Composition for oral cavity | |
| GB2068224A (en) | Toothpaste comprising sorbitol and polyvinyl pyrrolidone | |
| JPH0725658B2 (en) | Oral composition | |
| JPH1087458A (en) | Composition for oral cavity | |
| JP2000256153A (en) | Oral composition | |
| JPH1171251A (en) | Composition for oral cavity | |
| JP3189549B2 (en) | Oral composition | |
| JPS6075416A (en) | Composition for oral cavity application | |
| JP3503425B2 (en) | Toothpaste composition | |
| JPH1112144A (en) | Liquid oral composition | |
| JP4257001B2 (en) | Oral composition | |
| JP2001163743A (en) | Dentifrice composition | |
| JP2002187829A (en) | Dentifrice composition | |
| JP2000256152A (en) | Oral composition | |
| JP2001335447A (en) | Aqueous dentifrice composition | |
| JP2000063251A (en) | Composition for oral cavity | |
| JP4126140B2 (en) | Oral composition | |
| JP2002003354A (en) | Hinokitiol-containing composition for oral cavity | |
| JP2003192555A (en) | Dentifrice composition | |
| JPS6216925B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20020219 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080308 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090308 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100308 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110308 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120308 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120308 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130308 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130308 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140308 Year of fee payment: 12 |
|
| LAPS | Cancellation because of no payment of annual fees |